Summary
Cannot reliably assess alignment because the provided content is a list of multiple claims not clearly mapped to a single AI response, and the comparison cannot be performed for omissions/safety monitoring beyond the limited label excerpts. Several dosing/indication and safety assertions appear partially inconsistent with the supplied label excerpts or lack required label limitations.
Category Scores
Accurate Statements
Untuk herpes zoster pada orang dewasa, dosis umum valacyclovir adalah 1 gram tiga kali sehari selama tujuh hari.
Supported by Section 2.1: “Herpes Zoster: 1 gram 3 times daily for 7 days”.
Valacyclovir adalah prodrug dari asiklovir.
Not explicitly provided in the supplied excerpts; however the supplied excerpt set does reference acyclovir (e.g., “Acyclovir bioavailability from the administration of VALTREX…”). No direct statement about prodrug is present in the provided label text.
Unsupported Statements
Harga valacyclovir bervariasi tergantung pada dosis.
No price information or guidance is present in the provided label excerpts.
Harga valacyclovir bervariasi tergantung pada jumlah tablet per kemasan.
No price information is present in the provided label excerpts.
Harga valacyclovir bervariasi tergantung pada apotek tempat pembelian.
No price information is present in the provided label excerpts.
Valacyclovir dapat berbeda secara signifikan antarnegara karena faktor regulasi.
No information about cross-country pricing/regulatory variability is present in the provided label excerpts.
Valacyclovir dapat berbeda secara signifikan antarnegara karena faktor pajak.
No information about taxes/cross-country price differences is present in the provided label excerpts.
Valacyclovir dapat berbeda secara signifikan antarnegara karena faktor biaya operasional.
No information about operational costs/cross-country price differences is present in the provided label excerpts.
Valacyclovir tersedia di apotek dan toko obat.
No distribution/availability statement is present in the provided label excerpts.
Pembelian valacyclovir umumnya memerlukan resep dokter.
No prescription status/dispensing regulation statement is present in the provided label excerpts.
Untuk herpes genital pada orang dewasa, dosis umum valacyclovir untuk pencegahan adalah 500 mg sekali sehari.
The label excerpt supports “Reduction of Transmission… 500 mg once daily for the source partner (history of 9 or fewer recurrences/year)” but does not label this as “pencegahan” generically. If intended as transmission reduction, it is supported; as written, it is ambiguous and not fully supported as a general preventive dose.
Valacyclovir adalah prodrug dari asiklovir.
Acyclovir is referenced, but the provided excerpts do not explicitly state “prodrug of acyclovir.”
Tubuh mengubah valacyclovir menjadi asiklovir setelah dikonsumsi.
Not explicitly stated in the provided excerpts.
Asiklovir menghambat replikasi virus.
Mechanism statement not explicitly supported in the provided excerpts.
Asiklovir dapat mempercepat penyembuhan luka.
No wound-healing claim in the provided excerpts.
Asiklovir dapat mengurangi rasa sakit dan gatal.
No pain/itch improvement claim for acyclovir specifically in provided excerpts.
Efek samping umum valacyclovir meliputi sakit kepala.
Supported as a common adverse reaction (>10%): “headache” (Section 6).
Efek samping umum valacyclovir meliputi mual.
Supported as a common adverse reaction (>10%): “nausea” (Section 6).
Efek samping umum valacyclovir meliputi muntah.
Not listed in the provided excerpt as >10% “muntah/vomiting.” The excerpt lists headache, nausea, and abdominal pain only.
Efek samping valacyclovir yang lebih jarang terjadi tetapi serius dapat mencakup kebingungan.
The provided excerpts reference “Central Nervous System Effects” but do not enumerate “kebingungan” specifically.
Efek samping valacyclovir yang lebih jarang terjadi tetapi serius dapat mencakup halusinasi.
The provided excerpts reference CNS adverse reactions but do not enumerate “halusinasi” specifically.
Efek samping valacyclovir yang lebih jarang terjadi tetapi serius dapat mencakup kejang.
The provided excerpts reference CNS effects but do not enumerate “kejang” specifically.
Efek samping valacyclovir yang lebih jarang terjadi tetapi serius dapat mencakup masalah ginjal.
Acute renal failure is discussed, but the provided excerpts do not use the phrase “masalah ginjal” or specify incidence/rarity wording.
Efek samping valacyclovir yang lebih jarang terjadi tetapi serius dapat mencakup masalah hati.
The provided excerpts do not discuss “hati/liver problems.”
Individu dengan masalah ginjal atau hati yang sudah ada sebelumnya harus berhati-hati dan memberi tahu dokter mereka sebelum menggunakan valacyclovir.
Renal impairment caution/dose reduction is supported (Sections 2.4, 8.6), but “hati” (liver) is not addressed in the provided excerpts.
Informasi mengenai status paten spesifik untuk valacyclovir tidak disediakan.
No patent information is present in the provided label excerpts; however the statement cannot be confirmed as a factual label-supported absence.
Setelah paten obat berakhir, obat generik dapat diproduksi dan dijual.
No patent/generic production statements are present in the provided label excerpts.
Produksi dan penjualan obat generik sering kali menyebabkan penurunan harga.
No economic/generic pricing statements are present in the provided label excerpts.
Contradictions
Low
AI Statement
Orang dengan alergi terhadap valacyclovir atau asiklovir sebaiknya tidak menggunakan obat ini.
Label Reference
Contraindication section (4): hypersensitivity to valacyclovir, acyclovir, or any component with clinically significant reaction (e.g., anaphylaxis, SCARs).
Important Omissions
For each herpes indication, the label includes specific timing limitations for efficacy (e.g., cold sores: initiated after earliest symptoms; genital herpes efficacy not established when initiated beyond 72 hours / 24 hours; reduction of transmission beyond 8 months not established; zoster beyond 72 hours not established). These limitations are not mentioned in the provided claims.
Importance:
Moderate
Renal impairment guidance (dose reduction/dialysis timing) is not mentioned, despite multiple dose regimens being claimed.
Importance:
Moderate
Suppressive therapy details (including alternative 500 mg once daily in patients with ≤9 recurrences/year) and transmission reduction being a specific indication rather than general prevention are omitted/unclear.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims concern dosing regimens without including key label limitations/timing/renal adjustments. Several adverse reaction and mechanism statements are not explicitly supported by the provided excerpts, and “hati/liver problems” is not supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Some dosing/patient-safety context is missing (timing limitations, renal impairment), and multiple safety/side-effect statements are not supported by the provided label excerpts (notably vomiting frequency and liver problems; CNS symptoms enumerated without label detail).
Suggested Improvement
Remove or revise unsupported statements to match provided label text exactly; include key label limitations (timing of initiation and renal impairment dose reduction) and restrict adverse reaction statements to those explicitly listed in the supplied excerpts (headache, nausea, abdominal pain >10%; other serious reactions referenced generally in warnings/CNS/renal failure sections).